What Recent Market Trends Mean for Candel Therapeutics Inc’s (CADL) Stock

In the past week, CADL stock has gone up by 62.99%, with a monthly gain of 53.99% and a quarterly surge of 68.46%. The volatility ratio for the week is 7.14%, and the volatility levels for the last 30 days are 7.84% for Candel Therapeutics Inc The simple moving average for the last 20 days is 60.90% for CADL stock, with a simple moving average of 107.05% for the last 200 days.

Is It Worth Investing in Candel Therapeutics Inc (NASDAQ: CADL) Right Now?

Moreover, the 36-month beta value for CADL is 0.90. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The public float for CADL is 15.66M and currently, short sellers hold a 0.94% of that float. On April 04, 2024, CADL’s average trading volume was 83.88K shares.

CADL) stock’s latest price update

Candel Therapeutics Inc (NASDAQ: CADL) has seen a rise in its stock price by 49.40 in relation to its previous close of 1.68. However, the company has experienced a 62.99% gain in its stock price over the last five trading sessions. Proactive Investors reported 2023-12-12 that Candel Therapeutics shares gained more than 37% after the biopharmaceutical firm announced that its pancreatic cancer therapeutic has received U.S. Food and Drug Administration (FDA) Fast Track Designation.

Analysts’ Opinion of CADL

Many brokerage firms have already submitted their reports for CADL stocks, with H.C. Wainwright repeating the rating for CADL by listing it as a “Buy.” The predicted price for CADL in the upcoming period, according to H.C. Wainwright is $11 based on the research report published on December 02, 2022 of the previous year 2022.

BMO Capital Markets, on the other hand, stated in their research note that they expect to see CADL reach a price target of $18. The rating they have provided for CADL stocks is “Outperform” according to the report published on November 19th, 2021.

UBS gave a rating of “Buy” to CADL, setting the target price at $9 in the report published on August 23rd of the previous year.

CADL Trading at 63.68% from the 50-Day Moving Average

After a stumble in the market that brought CADL to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 28.72% of gains for the given period.

Volatility was left at 7.84%, however, over the last 30 days, the volatility rate increased by 7.14%, as shares surge +48.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +77.16% upper at present.

During the last 5 trading sessions, CADL rose by +51.85%, which changed the moving average for the period of 200-days by +65.85% in comparison to the 20-day moving average, which settled at $1.5979. In addition, Candel Therapeutics Inc saw 70.75% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for CADL

The total capital return value is set at -1.4. Equity return is now at value -125.50, with -63.12 for asset returns.

Based on Candel Therapeutics Inc (CADL), the company’s capital structure generated 0.63 points at debt to capital in total, while cash flow to debt ratio is standing at -1.57. The debt to equity ratio resting at 1.71. The interest coverage ratio of the stock is -51.19.

Currently, EBITDA for the company is -37.19 million with net debt to EBITDA at 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.59.


To wrap up, the performance of Candel Therapeutics Inc (CADL) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Related Posts